礼来公司推出“Employer Connect”，为新型多剂量Zepbound提供每月449美元的净价格，并与Teladoc Health和GoodRx等合作伙伴整合，以扩大肥胖药物的可及性；诺和诺德仍是主要竞争对手。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：张俊 SF065

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.